Mass spectrometric measurements of norepinephrine synthesis in man from infusion of stable isotope-labelled L-threo-3,4-dihydroxyphenylserine.
The kinetics of stable isotope-labelled L-threo-3, 4-dihydroxyphenylserine(L-threo-DOPS), an immediate precursor of (-)-norepinephrine, was studied to investigate the pharmacologic mechanism of its therapeutic effect on orthostatic hypotension in familial amyloid polyneuropathy(FAP) and on akinesia and freezing in parkinsonism. [13C,D]-L-threo-DOPS was synthesized, and 100 mg of the compound was infused for 2 h into two normal subjects, two FAP patients and two patients with the degenerative diseases of the central nervous system. Labelled and endogenous norepinephrine in urine and plasma was assayed simultaneously by gas chromatography/mass spectrometry. The results indicate that the increase in norepinephrine in biological fluids after administration of L-threo-DOPS is attributable mostly to norepinephrine derived from L-threo-DOPS, not to pre-formed endogenous norepinephrine released by L-threo-DOPS.
D001284:Atrophy; D001927:Brain Diseases / Q000188:drug therapy; D002531:Cerebellum / Q000473:pathology; D015103:Droxidopa / Q000627:therapeutic use*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007024:Hypotension, Orthostatic / Q000378:metabolism; D009638:Norepinephrine / Q000096:biosynthesis*; D009847:Olivary Nucleus / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy; D011149:Pons / Q000473:pathology; D012694:Serine / Q000031:analogs & derivatives*
D012694:Serine; D015103:Droxidopa; D009638:Norepinephrine